Exelixis Stock

Exelixis EBIT

The EBIT of Exelixis (EXEL) as of Aug 13, 2026 is 872.19 M USD. In the previous year, EBIT was 604.62 M USD — a change of 44.26% (higher).

EBIT

872.19 MUSD

YoY

44.26%

Last updated:

In 2026, Exelixis's EBIT was 872.19 M USD, a 44.26% increase from the 604.62 M USD EBIT recorded in the previous year.

The Exelixis EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B USD)
Date
EBIT (B USD)
Jan 1, 2023
0.17 base
Jan 1, 2024
0.60 base
Jan 1, 2025
0.87 base
Jan 1, 2026 (e)
1.49 base
Jan 1, 2027 (e)
1.69 base
Jan 1, 2028 (e)
1.86 base
Jan 1, 2029 (e)
1.98 base
Jan 1, 2030 (e)
1.75 base
YEAREBIT (B USD)
2030 est 1.75
2029 est 1.98
2028 est 1.86
2027 est 1.69
2026 est 1.49
2025 0.87
2024 0.60
2023 0.17
2022 0.20
2021 0.29
2020 0.11
2019 0.37
2018 0.44
2017 0.17
2016 -0.03
2015 -0.12
2014 -0.22
2013 -0.20
2012 -0.12
2011 0.09
2010 -0.09
2009 -0.12
2008 -0.18
2007 -0.16
2006 -0.13
Access this data via the Eulerpool API

Exelixis Revenue

Exelixis Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
1.83 B USD
170.89 M USD
207.77 M USD
Jan 1, 2024
2.17 B USD
604.62 M USD
521.27 M USD
Jan 1, 2025
2.32 B USD
872.19 M USD
782.57 M USD
Jan 1, 2026 (e)
2.55 B USD
1.49 B USD
1.01 B USD
Jan 1, 2027 (e)
2.87 B USD
1.69 B USD
1.15 B USD
Jan 1, 2028 (e)
3.24 B USD
1.86 B USD
1.33 B USD
Jan 1, 2029 (e)
3.44 B USD
1.98 B USD
1.38 B USD
Jan 1, 2030 (e)
3.05 B USD
1.75 B USD
1.16 B USD

Exelixis Margins

Exelixis stock margins

The Exelixis margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Exelixis. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Exelixis.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
96.04 %
9.34 %
11.35 %
Jan 1, 2024
96.49 %
27.88 %
24.04 %
Jan 1, 2025
96.39 %
37.59 %
33.73 %
Jan 1, 2026 (e)
96.39 %
58.49 %
39.41 %
Jan 1, 2027 (e)
96.39 %
58.63 %
39.90 %
Jan 1, 2028 (e)
96.39 %
57.47 %
41.19 %
Jan 1, 2029 (e)
96.39 %
57.47 %
40.16 %
Jan 1, 2030 (e)
96.39 %
57.47 %
38.02 %

Exelixis Stock analysis

What does Exelixis do? Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Exelixis's EBIT

Exelixis's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Exelixis's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Exelixis's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Exelixis’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Exelixis stock

EBIT of Exelixis is 872.19 M USD in 2026.

EBIT of Exelixis changed from 604.62 M USD to 872.19 M USD, representing a 44.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Exelixis since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Exelixis historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Exelixis

All Key Metrics — Exelixis